Sorting out brain-machine interface concept stocks with relatively low rolling price-to-earnings ratios.

Recently, brain-computer interface technology has seen intensive implementation in the domestic medical field, with multiple clinical breakthroughs announced in succession. More than 30 listed companies in the A-share market are engaging in brain-computer interface development. MylanD is conducting research and development focused on the integration of AI and non-invasive brain-computer interface technology, having initially established a technical system based on "brain signal collectionintelligent analysisstate recognitionclosed-loop feedback." Meihao Medical has assisted clients in the commercialization process from laboratory research to bulk shipments in the field of brain-computer interfaces, with related component products entering the small batch supply phase. Weis Medical focuses on the "non-invasive" technical route in the brain-computer interface field, striving to construct a closed-loop system that covers the entire cycle of "diagnosistreatmentrehabilitation." In terms of the secondary market, according to statistics from the Securities TimesData Treasure, as of the close on August 17, the average decline of brain-computer interface concept stocks this year is 8.55%, underperforming the Shanghai Composite Index during the same period. Four concept stocks have recorded a cumulative increase of over 10%, namely Shengshi Technology, Yingqu Technology, Darui Electronics, and Botao Biopharma.